BrainsWay
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16 Hartum St, Jerusalem, Jerusalem, 9777...Phone Number
+972 25824030Website
www.brainsway.comRevenue
$49.1 MillionStock Symbol
BWAYIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About BrainsWay
BrainsWay is an international medical device company founded in 2003 and headquartered in Jerusalem, Israel, specializing as a global leader in advanced noninvasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation platform technology. The company utilizes Deep Transcranial Magnetic Stimulation with unique patented technology developed in collaboration with the National Institute of Health. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies, with current indications including major depressive disorder, including reduction of anxiety symptoms commonly referred to as anxious depression, obsessive-compulsive disorder, and smoking addiction. The Deep TMS platform technology is also used for treatment of bipolar disorders, post traumatic stress disorders, schizophrenia, chronic pain, and other neurological and psychiatric conditions. The company serves doctors, hospiRead more
BrainsWay Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BrainsWay your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
BrainsWay, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BrainsWay launches new products
Earning: See what the market has to say on BrainsWay recently announced quarterly report
Click to see if BrainsWay had a recent Job posting/layoffs
Check out if BrainsWay is spiking on competitors!
Funding: Get notified immidiatlly once BrainsWay has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BrainsWay
Check if BrainsWay has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at BrainsWay
Find more new buyers
Company Profile Activity
Activity Insights
BrainsWay is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BrainsWay is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BrainsWay.
BrainsWay financials insights
Gather financial insights about BrainsWay, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$20M
BrainsWay Tech Stack
A closer look at the technologies used by BrainsWay
Most Recent Scoops
Person-Based
Healthcare Operations
Person-Based
Healthcare Operations, Medical Administration
Person-Based
Research & Development
Project
Spending/Investment
Earnings
Earnings, Finance
BrainsWay News & Media
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSDBrainsway CTO exercises options, sells 5,000 shares | BWAY Insider Trading - Stock Titan
Brainsway CTO Moiseyev Gilad exercised 7,500 options at NIS 11.17 and later sold 5,000 shares at NIS 42.0397, ending with 53,098 shares plus remaining options.BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 millioBrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0%
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BrainsWay
Sign Up For FreeTo access detailed company insights
BrainsWay is an international medical device company founded in 2003 and headquartered in Jerusalem, Israel, specializing as a global leader in advanced noninvasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation platform technology. The company utilizes Deep Transcranial Magnetic... Read More
